Skip to content

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, Luc Thomas, Igor Bondarenko, Steven J O'Day, Jeffrey S. Weber, Claus Garbe, Célèste Lebbé, Jean‐François Baurain, Alessandro Testori, Jean‐Jacques Grob, Neville G. P. Davidson, Jon M. Richards, Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascón, Michal Lotem, Kaan Harmankaya, Ramy A. Ibrahim, Tai‐Tsang Chen, Rachel W. Humphrey, Axel Hoos, Jedd D. Wolchok

New England Journal of Medicine · 2011 · 4,600 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Robert, C., Thomas, L., Bondarenko, I., O’Day, S. J., Weber, J. S., Garbe, C., Lebbé, C., Baurain, J., Testori, A., Grob, J., Davidson, N. G. P., Richards, J. M., Maio, M., Hauschild, A., Miller, W. H., Gascón, P., Lotem, M., Harmankaya, K., Ibrahim, R. A., … Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364(26), 2517–2526. https://doi.org/10.1056/nejmoa1104621

In text: (Robert et al., 2011)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma. METHODS: We randomly assigned 502 patients with previously untreated metastatic melanoma, in a 1:1 ratio, to ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter of body-surface area) or dacarbazine (850 mg per square meter) plus placebo, given at weeks 1, 4, 7, and 10, followed by dacarbazine alone every 3 weeks through week 22. Patients with stable disease or an objective response and no dose-limiting toxic effects received ipilimumab or placebo every 12 weeks thereafter as maintenance therapy. The primary end point was overall survival. RESULTS: Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (11.2 months vs. 9.1 months, with higher survival rates in the ipilimumab-dacarbazine group at 1 year (47.3% vs. 36.3%), 2 years (28.5% vs. 17.9%), and 3 years (20.8% vs. 12.2%) (hazard ratio for death, 0.72; P<0.001). Grade 3 or 4 adverse events occurred in 56.3% of patients treated with ipilimumab plus dacarbazine, as compared with 27.5% treated with dacarbazine and placebo (P<0.001). No drug-related deaths or gastrointestinal perforations occurred in the ipilimumab-dacarbazine group. CONCLUSIONS: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma. The types of adverse events were consistent with those seen in prior studies of ipilimumab; however, the rates of elevated liver-function values were higher and the rates of gastrointestinal events were lower than expected on the basis of prior studies. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00324155.).

  1. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer2016
  2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010
  3. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review2017
  4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
  5. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016

Metadata from OpenAlex (CC0). Citations are generated from the published record.